Small compounds for targeted radiotherapy
Metadata
Vis metadataFinnes i følgende samling
- Kjemisk institutt [1546]
Sammendrag
Sammendrag ikke registrert.Artikkelliste
I: E. M. Brevik, E. Årstad, P. Hoff. An improved synthesis of an 125I- and 211At-labelled benzamide for melanoma imaging. Proceedings of the 14th Radiochemical Conference, Mariánské Lázne 14–19 April 2002, Czech Republic. Czech. J. Phys. 53 (2003), Suppl.A A725–A729 |
II: E. M. Brevik, E. Årstad, P. Hoff. Synthesis and biodistribution of N-(2-diethylaminoethyl)-3-[211At]astato-4-methoxy-benzamide for targeted radiotherapy of malignant melanoma. Manuscript. To be submitted to Melanoma Research. |
III: E. M. Brevik, E. Årstad, F. O. Levy, P. Hoff. Evaluation of 125I- and 211At -labelled benzamides for targeting of s1-receptors in an amelanotic melanoma xenograft. Manuscript. To be submitted to Melanoma Research. |
IV: E. M. Brevik, K. H. Holm, D. S. Wilbur, D. K. Hamlin, P. Hoff. Syntheses and preliminary biodistribution studies of radioiodinated cysteaminylphenol derivatives for malignant melanoma. Manuscript. To be submitted to Nuclear Medicine and Biology. |
V: E. M. Brevik, A. Skretting, S. Bruheim, T. Bach-Gansmo, E. Årstad, P. Hoff. Pharmacokinetic properties and bone surface uptake of 1-hydroxy-(m-[123I]iodophenyl)-ethylidene-1,1-bisphosphonic acid (123I-HIPEBA) in pigs: implications for targeted radiotherapy. Manuscript. To be submitted to Nuclear Medicine Communications. |